These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27603206)

  • 1. National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
    Lin G; Zhang K; Yi L; Han Y; Xie J; Li J
    PLoS One; 2016; 11(9):e0162361. PubMed ID: 27603206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
    Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
    Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
    Binkhorst L; Mathijssen RH; Jager A; van Gelder T
    Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.
    Lyon E; Gastier Foster J; Palomaki GE; Pratt VM; Reynolds K; Sábato MF; Scott SA; Vitazka P;
    Genet Med; 2012 Dec; 14(12):990-1000. PubMed ID: 22955113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
    Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
    Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
    J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
    Margolin S; Lindh JD; Thorén L; Xie H; Koukel L; Dahl ML; Eliasson E
    Pharmacogenomics; 2013 Apr; 14(6):613-22. PubMed ID: 23570465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
    Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
    Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
    Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy.
    Mwinyi J; Vokinger K; Jetter A; Breitenstein U; Hiller C; Kullak-Ublick GA; Trojan A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1181-8. PubMed ID: 24682508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.
    Kiyotani K; Mushiroda T; Hosono N; Tsunoda T; Kubo M; Aki F; Okazaki Y; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    Pharmacogenet Genomics; 2010 Sep; 20(9):565-8. PubMed ID: 20574415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise.
    Lin G; Zhang X; Zhang K; Han Y; Tan L; Li J
    J Clin Lab Anal; 2018 Oct; 32(8):e22563. PubMed ID: 29708622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP2D6 polymorphisms on breast cancer recurrence.
    Morrow PK; Serna R; Broglio K; Pusztai L; Nikoloff DM; Hillman GR; Fontecha M; Li R; Michaud L; Hortobagyi G; Gonzalez-Angulo AM
    Cancer; 2012 Mar; 118(5):1221-7. PubMed ID: 21823108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coprescription of tamoxifen and medications that inhibit CYP2D6.
    Sideras K; Ingle JN; Ames MM; Loprinzi CL; Mrazek DP; Black JL; Weinshilboum RM; Hawse JR; Spelsberg TC; Goetz MP
    J Clin Oncol; 2010 Jun; 28(16):2768-76. PubMed ID: 20439629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ethics of CYP2D6 testing for patients considering tamoxifen.
    Hartman AR; Helft P
    Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.